BioVaxys Technology Corp. develops immunotherapies utilizing its DPX™ lipid-based delivery system and HapTenix© haptenization technology to enhance T-cell responses against tumor and viral antigens. The company targets advanced cancers, including relapsed-refractory diffuse large B-cell lymphoma and platinum-resistant ovarian cancer, through personalized vaccines and predictive algorithms for identifying new tumor antigens.
Funding
$537.5K raised to dateRaised to date based on public sources. This may differ from the amount the company actually raised and is based only on what is publicly available on the internet.
Founders
Product
Problem
Many advanced cancers and viral infections evade the immune system, limiting the effectiveness of traditional treatments. Current immunotherapy approaches often struggle to generate a robust and targeted T-cell response against tumor or viral antigens, hindering the body's ability to eliminate diseased cells.
Solution
BioVaxys Technology Corp. is developing immunotherapies that enhance T-cell responses against tumor and viral antigens. The company leverages its DPX™ lipid-based delivery system, acquired from IMV Inc., to encapsulate bioactive molecules and stimulate sustained immune responses. BioVaxys also utilizes its HapTenix© haptenization technology, which uses chemicals called ‘haptens’ to train the immune system to recognize and aggressively target tumor or viral proteins. This combined approach aims to create personalized vaccines and predictive algorithms for identifying new tumor antigens, ultimately improving treatment outcomes for advanced cancers and viral infections.
Target Audience
The primary target audience includes patients with advanced cancers, such as relapsed-refractory diffuse large B-cell lymphoma and platinum-resistant ovarian cancer, as well as individuals with viral infections.
Features
- DPX™ lipid-based delivery system for enhanced and sustained immune responses
- HapTenix© haptenization technology to enhance T cell response against tumor and viral antigens
- BVX-0918: Phase I vaccine candidate for Stage III/Stage IV ovarian cancer
- Personalized vaccines targeting advanced cancers
- Predictive algorithms for identifying new tumor antigens
- T cell-mediated immune response diagnostics